+1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
+1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
+1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
+1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
+1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
+1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Tricuspid) (NN valve) (NN regurgitation) (CC and) (NN lithium) (NN carbonate) (NN toxicity)) (PP (IN in) (NP (NP (DT a) (JJ newborn) (NN infant)) (: ;) (NP (DT A) (ADJP (JJ newborn) (PP (IN with) (NP (NP (JJ massive) (NN tricuspid) (NN regurgitation)) (, ,) (NP (JJ atrial) (NN flutter)) (, ,) (NP (JJ congestive) (NN heart) (NN failure)) (, ,) (CC and) (NP (DT a) (JJ high) (NN serum))))) (NN lithium) (NN level))))) (VP (VBZ is) (VP (VBN described)))) (: ;) (S (NP (DT This)) (VP (VBZ is) (NP (NP (DT the) (JJ first) (NN patient)) (PP (TO to) (NP (ADJP (ADVP (RB initially)) (JJ manifest)) (NN tricuspid) (NN regurgitation) (CC and) (JJ atrial) (NN flutter)))))) (, ,) (CC and) (S (S (NP (DT the) (JJ 11th)) (VP (VBN described) (NP (NP (NN patient)) (PP (IN with) (NP (JJ cardiac) (NN disease)))) (PP (IN among) (NP (NP (NNS infants)) (VP (VBN exposed) (PP (TO to) (NP (NN lithium) (NNS compounds))) (PP (IN in) (NP (NP (DT the) (JJ first) (NN trimester)) (PP (IN of) (NP (NN pregnancy)))))))))) (: ;) (S (NP (NP (CD Sixty-three) (NN percent)) (PP (IN of) (NP (DT these) (NNS infants)))) (VP (VBD had) (VP (VBN tricuspid) (NP (NP (NN valve) (NN involvement)) (: ;) (S (S (NP (NNP Lithium) (NN carbonate)) (VP (MD may) (VP (VB be) (NP (NP (DT a) (NN factor)) (PP (IN in) (NP (NP (DT the) (VBG increasing) (NN incidence)) (PP (IN of) (NP (JJ congenital) (NN heart) (NN disease)))))) (SBAR (WHADVP (WRB when)) (S (VP (VBN taken) (PP (IN during) (NP (JJ early) (NN pregnancy))))))))) (: ;) (S (NP (PRP It)) (ADVP (RB also)) (VP (VBZ causes) (NP (NP (JJ neurologic) (NN depression)) (, ,) (NP (NN cyanosis)) (, ,) (CC and) (NP (JJ cardiac) (NN arrhythmia))) (SBAR (WHADVP (WRB when)) (S (VP (VBN consumed) (PP (RB prior) (PP (TO to) (NP (NN delivery))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (NP (NP (JJ Phenobarbital-induced) (NN dyskinesia)) (PP (IN in) (NP (NP (DT a) (JJ neurologically-impaired) (NN child)) (: ;) (NP (NP (DT A) (JJ 2-year-old) (NN child)) (PP (IN with) (NP (JJ known) (JJ neurologic) (NN impairment))))))) (VP (VBD developed) (NP (DT a) (NN dyskinesia)) (ADVP (RB soon)) (PP (IN after) (S (VP (VBG starting) (NP (JJ phenobarbital) (NN therapy)) (PP (IN for) (NP (NP (NNS seizures)) (: ;) (VP (VBN Known) (SBAR (S (S (NP (NP (NNS causes)) (PP (IN of) (NP (NN movement) (NNS disorders)))) (VP (VBD were) (VP (VBN eliminated) (PP (IN after) (NP (NN evaluation)))))) (: ;) (S (PP (IN On) (NP (NP (NN repeat) (NN challenge)) (PP (IN with) (NP (NN phenobarbital))))) (, ,) (NP (DT the) (NN dyskinesia)) (VP (VBD recurred))) (: ;) (S (NP (NNP Phenobarbital)) (VP (MD should) (VP (VB be) (VP (VBN added) (PP (TO to) (NP (NP (DT the) (NN list)) (PP (IN of) (NP (JJ anticonvulsant) (NNS drugs))) (SBAR (WHNP (WDT that)) (S (VP (MD can) (VP (VB cause) (NP (NN movement) (NNS disorders))))))))))))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.0010475283488631248 2:0.0010667843744158745 3:0.010833841282874346 4:-0.0038681915029883385 5:0.00084978342056274414 6:0.0014792168512940407 7:0.0047137731453403831 8:-0.0051964761223644018 9:0.014285892713814974 10:0.015772329177707434 11:0.0082571598177310079 12:-0.01083602081052959 13:0.0021561347675742581 14:0.0063143682200461626 15:0.0055561478948220611 16:-0.016152631025761366 17:0.0035744425840675831 18:0.0096710787620395422 19:-0.0072075240314006805 20:-0.020919149741530418 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.015432540327310562 2:-0.009331938810646534 3:0.00037715141661465168 4:0.018394025042653084 5:0.0041519207879900932 6:-0.0024702162481844425 7:-0.00042793032480403781 8:0.0092011010274291039 9:0.012320596724748611 10:0.00029726233333349228 11:0.0075389943085610867 12:0.018154656514525414 13:0.013081250712275505 14:-0.0044457181356847286 15:0.0099576283246278763 16:-0.022013789042830467 17:-0.0024648807011544704 18:0.024193206802010536 19:0.019782464951276779 20:-0.020084451884031296 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.016837878152728081 2:-0.013826267793774605 3:-0.020634794607758522 4:0.012291068211197853 5:0.009279605932533741 6:0.022566633298993111 7:-0.022773457691073418 8:0.0040077054873108864 9:0.0071319909766316414 10:-0.015093719586730003 11:0.019956212490797043 12:0.014557775110006332 13:-0.023601902648806572 14:-0.01906895637512207 15:0.015141960233449936 16:0.012500153854489326 17:0.0091558676213026047 18:-0.0025572879239916801 19:-0.0040235463529825211 20:-0.018643666058778763 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0012165652588009834 22:0.0011066696606576443 23:0.015364203602075577 24:0.018869489431381226 25:-0.011043651029467583 26:0.018888184800744057 27:-0.020734114572405815 28:-0.0068787452764809132 29:0.016935659572482109 30:0.023131167516112328 31:-0.0023927444126456976 32:-0.00084987061563879251 33:0.00060142704751342535 34:0.0066605429165065289 35:-0.01033759955316782 36:0.024397851899266243 37:0.015864258632063866 38:0.023183170706033707 39:-0.022555550560355186 40:-0.011376131325960159  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:-0.012110039591789246 2:-0.017650453373789787 3:0.0048032822087407112 4:-0.019079068675637245 5:0.0088766245171427727 6:-0.0081402631476521492 7:-0.0032622294966131449 8:0.0039409496821463108 9:0.010209544561803341 10:0.021421553567051888 11:0.00030780181987211108 12:-0.0053853592835366726 13:0.00027362551190890372 14:0.020074402913451195 15:-0.0036574092227965593 16:-0.009108186699450016 17:0.020684612914919853 18:0.024543102830648422 19:-0.0073303887620568275 20:-0.017881534993648529 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0087606951128691435 22:-0.010574778949376196 23:-0.0073553011752665043 24:0.0060003327671438456 25:0.0074711962988658343 26:-0.0070634419098496437 27:-0.0012656739236263093 28:0.01342180953361094 29:-0.003724394366145134 30:0.0015827082097530365 31:0.0018833120702765882 32:0.0046424296451732516 33:0.014868893660604954 34:-0.0050577912479639053 35:0.0012193666771054268 36:0.019337989389896393 37:0.020444651134312153 38:-0.0013590529270004481 39:0.01064359163865447 40:-0.0077835503034293652  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.021905602887272835 22:-0.0093916831538081169 23:-0.00926181860268116 24:-0.014144194312393665 25:0.0080985408276319504 26:-0.015898371115326881 27:-0.02137283980846405 28:-0.0036345701664686203 29:-0.012804368510842323 30:0.013051856309175491 31:-0.009116816334426403 32:0.010472660884261131 33:0.00062601087847724557 34:-0.0218540970236063 35:-0.01806856133043766 36:-0.010206964798271656 37:-0.006627274677157402 38:0.022837866097688675 39:-0.023624906316399574 40:0.0079211918637156487  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0095129526453092694 22:-0.0033573816763237119 23:0.011206333059817553 24:-0.0074172255117446184 25:0.0047909483546391129 26:-0.0083261467516422272 27:0.0033652223646640778 28:0.0064228172414004803 29:-0.013330215821042657 30:0.0039018627721816301 31:-0.0019429260864853859 32:0.01147712925740052 33:0.0079030338674783707 34:-0.00494405347853899 35:0.023148139007389545 36:-0.0033876807428896427 37:-2.8983689844608307e-05 38:0.00042936671525239944 39:0.0066595021635293961 40:0.01034955179784447  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.021283524110913277 22:-0.011166516691446304 23:0.0091729713603854179 24:0.0092760324478149414 25:-0.017680099233984947 26:-0.0031819317955523729 27:-0.017345201224088669 28:0.013631659559905529 29:0.018184317275881767 30:-0.024318819865584373 31:0.022944033145904541 32:-0.023383773863315582 33:-0.023585081100463867 34:0.021946899592876434 35:0.016975767910480499 36:-0.019860781729221344 37:0.013899688608944416 38:-0.00032103472040034831 39:0.017082415521144867 40:-0.017079200595617294  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0034332535578869283 22:-0.0054887167643755674 23:-0.011024321611330379 24:-0.0097091526258736849 25:-0.00491686025634408 26:-0.0018884376622736454 27:-0.0019581206142902374 28:-0.0077929117251187563 29:0.010983371175825596 30:0.021203086711466312 31:-0.0044315704144537449 32:0.00394651317037642 33:-0.0017645205371081829 34:0.0065852646948769689 35:-0.00067235180176794529 36:-0.011923810932785273 37:-0.024412896484136581 38:-0.00038423528894782066 39:0.0010484335944056511 40:-0.0065931652206927538  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0028376593254506588 22:0.00057945342268794775 23:-0.014152465388178825 24:0.012419932521879673 25:-0.021112538874149323 26:0.00061738153453916311 27:0.014238525182008743 28:-0.010153751820325851 29:-0.021478757262229919 30:-0.009021267294883728 31:-0.015158613212406635 32:-0.0092838453128933907 33:-0.00011933925270568579 34:-0.0083484500646591187 35:-0.016493596136569977 36:-0.0098057817667722702 37:-0.018909575417637825 38:-0.015719080343842506 39:0.0055232644081115723 40:-0.0097368760034441948  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.00054927635937929153 22:0.0011827453272417188 23:-0.0069108225870877504 24:0.0030895203817635775 25:0.0011946805752813816 26:-0.0020635109394788742 27:0.015538480598479509 28:-0.013093578163534403 29:0.0083850605878978968 30:-0.0080127213150262833 31:-0.020451246295124292 32:-0.0002614213153719902 33:-0.004720667377114296 34:0.0054338299669325352 35:-0.0026341262273490429 36:-0.0093425897648558021 37:-0.011201399844139814 38:0.015836737584322691 39:0.012575206346809864 40:-0.0083037680014967918  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.010736912081483752 22:0.023073299787938595 23:0.021793912164866924 24:0.0095334788784384727 25:0.0041948272264562547 26:-0.0082551265368238091 27:0.00059828581288456917 28:-0.0076747318962588906 29:0.017581634223461151 30:0.002436232753098011 31:-0.0118254404515028 32:0.0047992432955652475 33:-0.016704216133803129 34:-0.015663046855479479 35:-0.014754875563085079 36:0.0048126592300832272 37:0.0073193868156522512 38:0.011611976195126772 39:-0.00076479697600007057 40:0.000323145417496562  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.016809510067105293 22:0.012388248927891254 23:-0.006232445128262043 24:-0.0073004867881536484 25:0.015113193541765213 26:0.017848167568445206 27:0.011142991483211517 28:-0.019688848406076431 29:-0.021193778142333031 30:0.019717402756214142 31:0.0039947060868144035 32:0.022637490183115005 33:-0.0033406061120331287 34:0.010526036843657494 35:-0.004046957939863205 36:-0.015160636976361275 37:-0.014637651853263378 38:0.0090566147118806839 39:0.0065717208199203014 40:0.017147712409496307  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.012634532526135445 22:0.023458272218704224 23:0.002448282903060317 24:-0.0087347226217389107 25:0.015883868560194969 26:-0.01871725358068943 27:0.022496458142995834 28:-0.0085152285173535347 29:-0.0064697987399995327 30:0.012151182629168034 31:0.016682611778378487 32:-0.0077433115802705288 33:-0.019340503960847855 34:0.0080805262550711632 35:-0.024861829355359077 36:-0.0034964191727340221 37:0.0050578266382217407 38:-0.013258566148579121 39:-0.0062033566646277905 40:0.019914707168936729  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.0058461222797632217 22:0.010429102461785078 23:0.010992282070219517 24:0.0083357472515975441 25:-0.0022297675022855401 26:0.01132556035493811 27:-0.00083710656811793649 28:-0.0065768637383977575 29:0.0079445640246073399 30:-0.0022979403923576078 31:-0.011517686769366264 32:0.00024323669883112112 33:-0.0086527001112699509 34:0.010420808723817268 35:-0.012478683143854141 36:-0.0096837583308418598 37:-0.007175808132160455 38:0.007738159891838829 39:-0.004081094016631444 40:-0.016807266355802614  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:0.0041125346130381031 22:0.0037716267009576163 23:0.010533736397822699 24:-0.0068048201501369476 25:0.00038501736707985401 26:0.0035443880284825959 27:0.011227822552124659 28:0.003304443322122097 29:0.016352084465324879 30:-0.0051449484502275782 31:-0.0018651870389779408 32:-0.0044397921301424503 33:-0.013595704765369495 34:0.0062333034196247654 35:0.0076578846201300621 36:0.012452879920601845 37:-0.013815412666493406 38:-0.0050882482125113411 39:0.002022626188894113 40:-0.0036721063661389053  |EV|
-1 |BT| (ROOT (S (S (NP (NP (JJ Acute) (NNS changes)) (PP (IN of) (NP (NN blood) (NN ammonia)))) (VP (MD may) (VP (VB predict) (NP (NP (JJ short-term) (JJ adverse) (NNS effects)) (PP (IN of) (NP (JJ valproic) (NN acid))))))) (: ;) (S (NP (NP (JJ Valproic) (NN acid)) (PRN (-LRB- -LRB-) (NP (NN VPA)) (-RRB- -RRB-))) (VP (VBD was) (VP (VBN given) (PP (TO to) (NP (NP (CD 24) (JJ epileptic) (NNS patients)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADVP (RB already)) (VP (VBG being) (VP (VBN treated) (PP (IN with) (NP (JJ other) (JJ antiepileptic) (NNS drugs))))))))))))) (: ;) (S (NP (NP (DT A) (JJ standardized) (NN loading) (NN dose)) (PP (IN of) (NP (NNP VPA)))) (VP (VBD was) (VP (VBN administered)))) (, ,) (CC and) (S (S (NP (JJ venous) (NN blood)) (VP (VBD was) (VP (VBN sampled) (PP (IN at) (NP (NP (CD 0)) (, ,) (NP (CD 1)) (, ,) (NP (CD 2)) (, ,) (NP (CD 3)) (, ,) (CC and) (NP (CD 4) (NNS hours))))))) (: ;) (S (S (NP (NP (NNP Ammonia)) (PRN (-LRB- -LRB-) (NP (NN NH3)) (-RRB- -RRB-))) (VP (VBD was) (ADJP (JJR higher)) (PP (IN in) (NP (NP (NNS patients)) (SBAR (WHNP (WP who)) (S (, ,) (PP (IN during) (NP (JJ continuous) (NN therapy))) (, ,) (VP (VBD complained) (PP (IN of) (NP (NP (NN drowsiness)) (PRN (-LRB- -LRB-) (NP (CD 7) (NNS patients)) (-RRB- -RRB-)))) (PP (IN than) (IN in) (NP (NP (DT those)) (SBAR (WHNP (WP who)) (S (VP (VBD were) (ADJP (JJ symptom-free)))))))))) (PRN (-LRB- -LRB-) (NP (CD 17) (NNS patients)) (-RRB- -RRB-)))) (, ,) (SBAR (IN although) (S (NP (NNP VPA) (NN plasma) (NNS levels)) (VP (VBD were) (ADJP (JJ similar) (PP (IN in) (NP (DT both) (NNS groups))))))))) (: ;) (S (PP (IN By) (S (VP (VBG measuring) (NP (NP (JJ VPA-induced) (NNS changes)) (PP (IN of) (NP (NN blood) (NN NH3) (NN content))))))) (, ,) (NP (PRP it)) (VP (MD may) (VP (VB be) (ADJP (JJ possible) (S (VP (TO to) (VP (VB identify) (NP (NNS patients)) (PP (IN at) (NP (NP (JJR higher) (NN risk)) (PP (IN of) (NP (NN obtundation))))))))) (SBAR (WHADVP (WRB when)) (S (NP (NNP VPA)) (VP (VBZ is) (VP (VBN given) (ADVP (RB chronically))))))))))) (: ;))) |ET| |BV| 1:0.019122123718261719 2:0.012861873954534531 3:0.02163119800388813 4:0.023774987086653709 5:-0.010670226998627186 6:-0.0012378555256873369 7:0.021244781091809273 8:-0.023108310997486115 9:0.017532050609588623 10:0.022447757422924042 11:0.018980406224727631 12:0.013436945155262947 13:0.016972752287983894 14:0.011970462277531624 15:-0.00011027176515199244 16:-0.011410984210669994 17:0.018959060311317444 18:-0.00099664484150707722 19:-0.0027553429827094078 20:-0.0073137129656970501 21:-0.00094830134185031056 22:-0.014447032008320093 23:-0.0032524126581847668 24:-0.0084512850735336542 25:-0.0023796935565769672 26:0.0049515588907524943 27:0.016707603819668293 28:-0.004390818765386939 29:0.0078044235706329346 30:0.0055674687027931213 31:-0.0022708228789269924 32:-0.01431247522123158 33:0.010132071562111378 34:-0.004883726011030376 35:0.0095900434534996748 36:0.00016949651762843132 37:-0.015996766742318869 38:0.0049442844465374947 39:0.0078572931233793497 40:0.0082063295412808657  |EV|
